Vator Securities: Diamyd® on track for Phase III with 50% LOA, targeting a multibillion-dollar market as a precision medicine game changer
As of September 15th, 2020, the company that was founded in 1984 delivered convincing top-line data – in line with medical consensus view of implementing precision medicine – consistently supporting positive effect of the first-in-class disease-modifying diabetes vaccine Diamyd® in a genetically defined group. The patient group constitutes approximately 40% of patients with type 1 diabetes (T1D) and is delineated by patients positive for the human leukocyte antigen DR3-DQ2 haplotype and GAD autoantibodies. The fresh prospective topline-data from the Phase IIb study DIAGNODE-2 has now